Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Tobii Technology in funding round led by Intel Capital
Mandate

Vinge advises Tobii Technology in funding round led by Intel Capital

March 23, 2012

Vinge has advised Tobii Technology AB on a USD 21 million investment by Intel Capital. Tobii Technology is the global leader in eye tracking and gaze interaction. Founded in 2001, Tobii continues to achieve rapid annual growth and receive awards and recognition for its accomplishments. Based in Sweden, Tobii has a global presence, with offices in the U.S., China, Germany, Japan and Norway. The funding by Intel will be used to continue R&D investments in core technology and to take eye tracking and gaze interaction to mainstream computers and other mass-market applications.

Vinge's team consisted of partner Johan Winnerblad together with associates Matthias Pannier and Karl Hahtovirta.

Related

Vinge advises Axcel and Sanviva on the acquisitions of DermaCura and YourRad

 Vinge has advised Axcel Elevate I and Sanviva in connection with the acquisitions of DermaCura and YourRad.
September 07, 2026

Vinge advises Revivo Group on the acquisition of Premator

 Revivo Group AB has acquired all the shares in Premator AB, the parent company of a group operating in the field of advanced surface treatment with extensive experience in shot blasting, anti-corrosion painting and related services. Operations are conducted in Sweden, Norway and Denmark.
September 03, 2026

Vinge advises the sellers on the sale of Nextory to Bonnier Books

 Vinge has acted as legal adviser to the sellers in connection with Bonnier Books’ acquisition of Nextory, one of Europe’s leading streaming services for audiobooks and e-books. Bonnier Books is acquiring all shares in Nextory, and the transaction comprises Nextory’s operations in Sweden and internationally. The acquisition is a cash transaction and the parties have agreed not to disclose the purchase price. The transaction is subject to customary regulatory approvals.
September 02, 2026